Compare TCBK & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCBK | IMCR |
|---|---|---|
| Founded | 1975 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | 524 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1995 | 2016 |
| Metric | TCBK | IMCR |
|---|---|---|
| Price | $50.65 | $28.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $54.60 | ★ $66.33 |
| AVG Volume (30 Days) | 73.1K | ★ 314.6K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | 6.94 | ★ 30.39 |
| EPS | ★ 1.04 | 0.25 |
| Revenue | $53,445,000.00 | ★ $249,428,000.00 |
| Revenue This Year | $12.03 | $14.57 |
| Revenue Next Year | $4.47 | $8.21 |
| P/E Ratio | ★ $48.36 | $115.42 |
| Revenue Growth | 4.12 | ★ 43.05 |
| 52 Week Low | $38.36 | $27.56 |
| 52 Week High | $53.18 | $40.71 |
| Indicator | TCBK | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | 46.58 |
| Support Level | $48.42 | $27.69 |
| Resistance Level | $51.09 | $31.56 |
| Average True Range (ATR) | 0.91 | 1.09 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 74.30 | 42.56 |
TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.